Hengrui Pharma(SH:600276) Sou Hu Cai Jing·2025-12-08 09:59Core Viewpoint - Heng Rui Medicine (600276) has seen a positive market response following the announcement of multiple drugs being included in the National Medical Insurance Directory for 2025, which is expected to enhance its revenue potential significantly [1]. Group 1: Stock Performance - As of December 8, 2025, Heng Rui Medicine closed at 62.46 CNY, up 1.36% from the previous trading day, with a total market capitalization of 414.56 billion CNY [1]. - The stock opened at 62.6 CNY, reached a high of 63.55 CNY, and a low of 61.92 CNY, with a trading volume of 3.187 billion CNY and a turnover rate of 0.8% [1]. Group 2: Drug Inclusion in National Insurance - Heng Rui Medicine announced that several of its drugs have been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Directory for 2025 [1]. - Newly included drugs are injection of Rukang Qutuzumab and Apixaban Famitin Capsules, while additional indications for drugs like injection of Karilizumab and Fluorouracil Capsules have also been added [1]. - The total sales for these drugs are projected to be approximately 8.66 billion CNY for the year 2024 and about 7.554 billion CNY for the first three quarters of 2025 [1]. - The new insurance directory will be implemented starting January 1, 2026, with specific payment standards to be announced officially [1].